Skip to content

ASP Isotopes, Inc. ASPI Collaboration Revenue — Revenue

Similar metrics at other companies

Esperion Therapeutics logo
ESPRCollaboration revenue — Total Revenues
$36.71M+22.0%
Nurix Therapeutics, Inc. logo
NRIXCollaboration revenue — Revenue
$6.25M-66.1%
Alumis Inc. logo
ALMSCollaboration Revenue — Revenue
$1.74M
Adaptive Biotechnologies logo
ADPTCollaboration Revenue — Revenue
$0-100%
Viridian Therapeutics, Inc. logo
VRDNCollaboration — Total revenues
$135K+35.0%
CRISPR Therapeutics logo
CRSPCollaboration Revenue — Revenue
$1M

Other financials

Income statement

See full
Revenue$4.2M+279%
Gross profit$1.7M+409%
Operating income-$24.9M-213%
Net income-$7.1M+15.8%
EPS (diluted)-$0.06+50.0%

Balance sheet

See full
Cash & equivalents$211.7M+278%
Total debt$61.9M+1,787%
Total equity$289.0M+580%
Total assets$587.7M+547%

Cash flow

See full
Operating cash flow-$17.8M-460%
CapEx$6.1M+166%
Free cash flow-$23.9M-336%

Valuation

See full
Market cap$888.88M+40.0%
Enterprise value$739.08M+26.9%
P/S33×-111×

Profitability

See full
Gross margin17.6%-19.8pp
Operating margin-285.4%-102pp
Net margin-588.6%-112pp
FCF margin-244.6%-92.7pp

Returns & leverage

See full
Return on equity-95.6%-19.3pp
Debt / equity0.2×+0.1×
Current ratio4.4×-2.8×

Where this comes from

Reported directly by ASP Isotopes, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: ASP Isotopes, Inc.’s 10-Q, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about ASP Isotopes, Inc.'s collaboration revenue — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ASP Isotopes, Inc.'s collaboration revenue — revenue?
ASP Isotopes, Inc. (ASPI) reported collaboration revenue — revenue of $200K in Q1 2026.
What does collaboration revenue — revenue mean?
This metric represents the total revenue generated from strategic partnerships, joint development agreements, or collaborative research initiatives focused on isotope enrichment technologies. It captures income derived from shared development efforts rather than direct commercial product sales. Monitoring this stream provides insight into the company's ability to monetize its intellectual property and technical expertise during the pre-commercial development phase.